AstraZeneca’s Sone-Ve improves overall survival in Phase III gastric cancer trial

By Public Technologies
  • AstraZeneca will present overall survival data from four pivotal Phase III trials at the ESMO Congress, October 23-27, 2026.
  • CLARITY-Gastric01 showed Sone-Ve improved survival versus investigator-selected therapy in previously treated patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer.
  • SAFFRON results will highlight the clinical benefit of adding Orpathys to Tagrisso in previously treated, MET-driven, EGFR-mutated lung cancer.
  • VOLGA and DeLLphi-305 findings will showcase Imfinzi combinations’ potential to improve treatment in bladder cancer and extensive-stage small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202610190206BITN____UKPR__SV_20261018-BIT-4883-0) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.